Survival rate

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers

Retrieved on: 
Tuesday, October 24, 2023
Patient, SCLC, US, Therapy, Antigen, US FDA, Neuroendocrine carcinoma of the cervix, Doctor of Philosophy, Carcinoma, OBT, NEC Laboratories America, ADC, Boehringer Ingelheim, Partnership, Cancer, Survival rate, Lymphocyte, DLL3, Vaccine, Pharmaceutical industry, Medicine

The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.

Key Points: 
  • The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.
  • Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “The start of this Phase 2 trial with BI 764532, the most advanced candidate with our partner Boehringer Ingelheim which was discovered using our proprietary OGAP® platform, is a major milestone for OBT.
  • Patients with neuroendocrine carcinomas, including small cell lung cancer, have a 5-year survival rate of approximately 13%.
  • BI 764532 was discovered using OBT’s proprietary OGAP® drug discovery platform and Boehringer Ingelheim’s longstanding expertise in oncology through a successful partnership initiated in 2013.

Mediacom and Employees Raise Over $30,000 for Breast Cancer Awareness & Research

Retrieved on: 
Tuesday, October 24, 2023
Carriers and Services, Mobile, Wireless, Networks, Professional Services, Internet, Philanthropy, Oncology, Technology, Fund Raising, Audio, Video, Health, Environmental, Social and Governance (ESG), Telecommunications, American Cancer Society, Mediacom, Garnet Health, Research, Administration, Friends, Paramjeet Singh, Surgical oncology, Survival rate, Breast cancer, Woman, Birth control

Mediacom Communications and its employees proudly participated in the annual Making Strides of Hudson Valley walk day raising over $30,000 for the American Cancer Society.

Key Points: 
  • Mediacom Communications and its employees proudly participated in the annual Making Strides of Hudson Valley walk day raising over $30,000 for the American Cancer Society.
  • A Mediacom specific event was hosted at the company’s Mediacom Park headquarters where attendees walked along the property’s nature trail.
  • “Mediacom is proud to continue supporting the fight against Breast Cancer by participating in Making Strides for the ninth consecutive year,” said Catherine Commisso, Mediacom’s Group VP of Administration.
  • “We hope that women can achieve a better survival rate and someday have the possibility of eliminating breast cancer as the second leading cancer death for women.”

Latin Media, Artists, Content Creators Unite at Promesa y Esperanza® Seminar to Support St. Jude Children’s Research Hospital®

Retrieved on: 
Tuesday, October 24, 2023
Influencer, Communications, Celebrity, Oncology, Philanthropy, Hospitals, Music, Children, Hispanic, Fund Raising, Science, Entertainment, Consumer, Health, Research, Child, Latin, Housing, Food, Life, TelevisaUnivision, NCI-designated Cancer Center, Hope, ALSAC, Promesa, Multimedia, National Cancer Institute (Egypt), National Cancer Institute, Survival rate, Love, Travel, St. Jude Children's Research Hospital, Cancer, Bustos Media, Patient, Hospital, Nightclub, Jude the Apostle

More than 250 attendees spanning Spanish-language media, celebrities and content creators gathered last weekend for the St. Jude Promesa y Esperanza® seminar in support of the mission of St. Jude Children’s Research Hospital : Finding cures.

Key Points: 
  • More than 250 attendees spanning Spanish-language media, celebrities and content creators gathered last weekend for the St. Jude Promesa y Esperanza® seminar in support of the mission of St. Jude Children’s Research Hospital : Finding cures.
  • View the full release here: https://www.businesswire.com/news/home/20231024436490/en/
    St. Jude patient Ashley joins the stage with DannyLux during the St. Jude Promesa y Esperanza® seminar at St. Jude Children's Research Hospital.
  • Guests were also welcomed to the St. Jude campus where they heard from St. Jude researchers, met patients, their families and experienced performances by Latin artists.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

Retrieved on: 
Tuesday, October 24, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, ESMO, SCCHN, Target, Congress, Head, European Society for Medical Oncology, Risk, Physician, Survival rate, Patient, Death, Neck, Plasma protein binding, Pharmaceutical industry, Injection

CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data’s impact on propelling the Company’s immunotherapy drug Multikine* (Leukocyte Interleukin, Injection) toward regulatory approval for the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN).

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data’s impact on propelling the Company’s immunotherapy drug Multikine* (Leukocyte Interleukin, Injection) toward regulatory approval for the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN).
  • Mr. Kersten carefully explains how it is that patients in the target group who were treated with Multikine had a 5-year survival rate of 73% as compared to only 45% for those who did not receive Multikine, cutting the risk of death by half.
  • He goes on to present CEL-SCI’s regulatory submissions plan and timelines based on these compelling findings for a patient population that has not had a new treatment approved in in the U.S. in many decades.
  • Summary of Multikine Results in the Target Population:
    Target population of an estimated 145,000 patients (global, annual) who present with:
    Physicians routinely assess these features at baseline; no extra tests needed
    These features make it easy to write a label for the approval of Multikine, which is essential for drug approval

LG BROADENS 'MISSION FOR THE FUTURE' INITIATIVE, ENABLING MORE INNOVATORS TO CHANGE THE WORLD

Retrieved on: 
Wednesday, October 25, 2023
Mission, Electronics, ESG, NOVA, LG, Head, Corporation, Software, Artificial intelligence, Growth, LG Electronics, Survival rate, Future, Investment, Automation, Robotics, Management, Pharmaceutical industry

 SAN FRANSCISCO, Oct. 25, 2023 /PRNewswire/ -- LG NOVA, LG Electronics' North American Innovation Center, has launched the next version of its Mission for the Future program designed to discover, build and grow highly impactful mission-driven new businesses in collaboration with startups and entrepreneurs. The program, accumulating more than 3,500 submissions from startups over the last two years, is shifting to a year-round process to increase its ability to deeply engage with selected companies to advance technology innovations and build new ventures that will help create transformational positive change in the world.

Key Points: 
  • The cleantech category includes companies working on software and platform for efficient energy management, sustainability, ESG initiatives for better planet health.
  • Startups, companies and entrepreneurs are invited to submit their ideas to work and grow their company with LG, a global brand leader in consumer electronics, at www.lgnova.com/join-the-mission .
  • Rhee said LG NOVA's program has demonstrated "remarkable success in fostering interest, innovation and collaboration across industries."
  • Last year, LG received more than 2,100 applications, with 756 applications focusing on digital health, 783 applications in futuretech and 574 applications in cleantech.

Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Technology, Health, Radiology, Oncology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, Survival, FDA, LP, NMPA, Medical device, Q2, Lung cancer, Medicine, Mortality, US Foods, Chinese, Software, Euronext Growth, Q3, Business, Cave rescue, Survival rate, Patient, EIB, Diagnosis, LCS, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Median

Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).

Key Points: 
  • Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).
  • Commenting on the results, Fredrik Brag, CEO, and co-founder of Median Technologies, said:
    “During the first three quarters of 2023, we made significant strides regarding iBiopsy®.
  • These are key milestones in our roadmap to obtain marketing authorizations for our Software as Medical Device for the US and European markets.
  • Median is poised to play a pivotal role to help significantly reduce the lung cancer mortality rate through more effective diagnosis of early-stage patients.

New Study Using Biological Dynamics’ ExoVerita Platform Validates Exosome Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC)

Retrieved on: 
Thursday, October 19, 2023
Managed Care, Research, Other Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, Neoplasm, Survival, Biomarker, II, Oregon Health & Science University, Exosome, Detection, Cell, Nanoparticle, Biological Dynamics of Forest Fragments Project, Disease, Cancer, OHSU, Machine learning, Survival rate, Pancreatic cancer, PDAC, Pharmaceutical industry, Medical imaging, Verita

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.
  • Biological Dynamics’ ExoVita Pancreas assay, powered by the ExoVerita™ platform, uses the AC Electrokinetics method for exosome isolation.
  • “Driven by our Verita technology, the ExoVita test can detect challenging diseases like pancreatic cancer earlier than ever.
  • With further testing in real-world settings, we are confident our exosome enabled test will be useful for high-risk surveillance and early detection of pancreatic cancer, resulting in improved patient outcomes.”

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Olympus Announces Market Launch of EVIS X1™ Endoscopy System

Retrieved on: 
Thursday, October 19, 2023
American Cancer Society, GI, Colon, Ulcer, American College, Endoscopy, Olympus Corporation, Physician, ACG, Polyp, Colorectal cancer, TXI, RDI, American College of Gastroenterology, Multimedia, Texture, Laparoscopy, Crohn's disease, Quality of life, CRC, NBI, Maintenance, Survival rate, Woman, Narrow-band imaging, Coeliac disease, Brightness, Patient, Diagnosis, Medical imaging, Medical device, Online shopping, Dairy

CENTER VALLEY, Pa., Oct. 19, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today the market launch of its next-generation EVIS X1™ endoscopy system, which will be on display and demonstrated Oct. 22-24 during the American College of Gastroenterology (ACG) annual meeting in Vancouver, Canada.

Key Points: 
  • The EVIS X1 endoscopy system received clearance earlier this year along with two compatible endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract.
  • These are adjunctive tools for endoscopic examination that can be used to supplement Olympus white light imaging.
  • The addition of new imaging technologies in the EVIS X1 endoscopy system may help physicians to visualize these abnormalities.
  • Olympus' portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments.